Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

Malcolm K. Brenner; Donna R. Rill; Robert C. Moen; Robert A. Krance; Joseph Mirro; W. French Anderson; James N. Ihle

doi:10.1016/0140-6736(93)92560-G

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

Malcolm K. Brenner, Donna R. Rill, Robert C. Moen, Robert A. Krance, Joseph Mirro, W. French Anderson, James N. Ihle

Research output: Contribution to journal › Article › peer-review

894 Scopus citations

Abstract

Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.

Original language	English (US)
Pages (from-to)	85-86
Number of pages	2
Journal	The Lancet
Volume	341
Issue number	8837
DOIs	https://doi.org/10.1016/0140-6736(93)92560-G
State	Published - Jan 9 1993

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/0140-6736(93)92560-G

Cite this

@article{3986f38b0ae0400695f03d34ce808497,

title = "Gene-marking to trace origin of relapse after autologous bone-marrow transplantation",

abstract = "Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.",

author = "Brenner, {Malcolm K.} and Rill, {Donna R.} and Moen, {Robert C.} and Krance, {Robert A.} and Joseph Mirro and Anderson, {W. French} and Ihle, {James N.}",

note = "Funding Information: This study was supported by grants 5 P01 CA 20180 and CA 21765 (Core) from the National Institutes of Health and by the American Lebanese Syrian Associated Charities (ALSAC).",

year = "1993",

month = jan,

day = "9",

doi = "10.1016/0140-6736(93)92560-G",

language = "English (US)",

volume = "341",

pages = "85--86",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8837",

}

TY - JOUR

T1 - Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

AU - Brenner, Malcolm K.

AU - Rill, Donna R.

AU - Moen, Robert C.

AU - Krance, Robert A.

AU - Mirro, Joseph

AU - Anderson, W. French

AU - Ihle, James N.

N1 - Funding Information: This study was supported by grants 5 P01 CA 20180 and CA 21765 (Core) from the National Institutes of Health and by the American Lebanese Syrian Associated Charities (ALSAC).

PY - 1993/1/9

Y1 - 1993/1/9

N2 - Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.

AB - Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.

UR - http://www.scopus.com/inward/record.url?scp=0027471156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027471156&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(93)92560-G

DO - 10.1016/0140-6736(93)92560-G

M3 - Article

C2 - 8093407

AN - SCOPUS:0027471156

SN - 0140-6736

VL - 341

SP - 85

EP - 86

JO - The Lancet

JF - The Lancet

IS - 8837

ER -

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this